NCT03033433View on ClinicalTrials.gov

DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

August 31, 2018

Conditions
Type2 Diabetes
Interventions
DRUG

DCB-DM101

determination of optimal dose for Stage 2

Trial Locations (1)

114

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

VitNovo, Inc.

INDUSTRY

NCT03033433 - DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients | Biotech Hunter | Biotech Hunter